Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

IF 3.2 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo
{"title":"Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?","authors":"Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo","doi":"10.1002/ehf2.15165","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Knowledge of the effects of sex in cardio-oncology is limited, particularly in patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML). This study aims to evaluate the influence of gender differences on the incidence of cardiovascular toxicity in patients with CML.</p><p><strong>Methods: </strong>The study population consisted of 148 patients (45% women, mean age: 58 ± 14.2 years) diagnosed with CML treated with TKIs. The HFA-ICOS score estimated cardiovascular risk. The HFA-ICOS score revealed that 12% of men and 6% of women were categorized as very high risk while 45% of men and 50% of women fell into the high-risk group. Myocardial ischaemia, peripheral artery disease, venous thromboembolism, pulmonary hypertension and new-onset arterial hypertension during treatment with TKIs were recorded.</p><p><strong>Results: </strong>The incidence of global events between men and women was comparable (35% vs 32%, P = 0.68). There were 33% who experienced a cardiovascular event during TKI therapy, with a significant sex difference in arterial thrombosis incidence (P = 0.02) and venous thrombosis incidence (P = 0.02). Patients treated with ponatinib had a 41% event rate, followed by nilotinib (32%) and imatinib (32%). The HFA-ICOS score demonstrated greater predictive efficacy for events in the female group [area under the curve (AUC) = 0.797] compared with the male group (AUC = 0.537). Very high [hazard ratio (HR) 3.07; confidence interval (CI) 1.11, 8.47 P = 0.03] and high (HR 3.29; CI 1.17, 9.26 P = 0.02) HFA-ICOS scores were associated with increased event risk, particularly in women. Diabetes was women's strongest predictor of events (HR 5.40; CI 1.37, 21.3 P = 0.01).</p><p><strong>Conclusions: </strong>Our study showed a similar frequency of cardiovascular events between men and women. Accurate cardiovascular risk stratification with HFA-ICOS score in cancer patients is crucial. Diabetes and the HFA-ICOS score were significant predictors of events in the female groups. A sex approach in clinical practice could be pursued to improve the appropriateness of care.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ehf2.15165","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Knowledge of the effects of sex in cardio-oncology is limited, particularly in patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML). This study aims to evaluate the influence of gender differences on the incidence of cardiovascular toxicity in patients with CML.

Methods: The study population consisted of 148 patients (45% women, mean age: 58 ± 14.2 years) diagnosed with CML treated with TKIs. The HFA-ICOS score estimated cardiovascular risk. The HFA-ICOS score revealed that 12% of men and 6% of women were categorized as very high risk while 45% of men and 50% of women fell into the high-risk group. Myocardial ischaemia, peripheral artery disease, venous thromboembolism, pulmonary hypertension and new-onset arterial hypertension during treatment with TKIs were recorded.

Results: The incidence of global events between men and women was comparable (35% vs 32%, P = 0.68). There were 33% who experienced a cardiovascular event during TKI therapy, with a significant sex difference in arterial thrombosis incidence (P = 0.02) and venous thrombosis incidence (P = 0.02). Patients treated with ponatinib had a 41% event rate, followed by nilotinib (32%) and imatinib (32%). The HFA-ICOS score demonstrated greater predictive efficacy for events in the female group [area under the curve (AUC) = 0.797] compared with the male group (AUC = 0.537). Very high [hazard ratio (HR) 3.07; confidence interval (CI) 1.11, 8.47 P = 0.03] and high (HR 3.29; CI 1.17, 9.26 P = 0.02) HFA-ICOS scores were associated with increased event risk, particularly in women. Diabetes was women's strongest predictor of events (HR 5.40; CI 1.37, 21.3 P = 0.01).

Conclusions: Our study showed a similar frequency of cardiovascular events between men and women. Accurate cardiovascular risk stratification with HFA-ICOS score in cancer patients is crucial. Diabetes and the HFA-ICOS score were significant predictors of events in the female groups. A sex approach in clinical practice could be pursued to improve the appropriateness of care.

TKIs在慢性髓性白血病患者中引起的心血管毒性:女性和男性不同吗?
目的:性别对心血管肿瘤的影响的认识是有限的,特别是在慢性髓性白血病(CML)的酪氨酸激酶抑制剂(TKIs)治疗的患者中。本研究旨在评估性别差异对CML患者心血管毒性发生率的影响。方法:研究人群包括148例经TKIs治疗的CML患者(45%为女性,平均年龄:58±14.2岁)。HFA-ICOS评分评估心血管风险。HFA-ICOS评分显示,12%的男性和6%的女性被归为高危人群,45%的男性和50%的女性属于高危人群。记录TKIs治疗期间心肌缺血、外周动脉疾病、静脉血栓栓塞、肺动脉高压和新发动脉高血压。结果:男性和女性的全球事件发生率相当(35% vs 32%, P = 0.68)。有33%的患者在TKI治疗期间发生心血管事件,动脉血栓发生率(P = 0.02)和静脉血栓发生率(P = 0.02)的性别差异有统计学意义。波纳替尼治疗的患者事件发生率为41%,其次是尼洛替尼(32%)和伊马替尼(32%)。与男性组(AUC = 0.537)相比,HFA-ICOS评分对女性组事件的预测效果更强[曲线下面积(AUC) = 0.797]。非常高[风险比(HR) 3.07;置信区间(CI) 1.11, 8.47, P = 0.03)和高(HR 3.29;CI 1.17, 9.26 P = 0.02) HFA-ICOS评分与事件风险增加相关,尤其是女性。糖尿病是女性事件的最强预测因子(HR 5.40;Ci 1.37, 21.3 p = 0.01)。结论:我们的研究显示,男性和女性发生心血管事件的频率相似。利用HFA-ICOS评分对癌症患者进行准确的心血管风险分层至关重要。糖尿病和HFA-ICOS评分是女性组事件的重要预测因子。在临床实践中,可以采用性别方法来提高护理的适当性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信